```html

Iridocyclitis – Comprehensive Medical Guide

Overview

Iridocyclitis is inflammation of the iris (the colored part of the eye) and the ciliary body (the muscle that helps the eye focus). When both structures are inflamed together, the condition is often simply called “anterior uveitis.” It is the most common form of uveitis, accounting for roughly 80–90 % of all uveitis cases.

• Who it affects: Adults between 20 and 50 years are most often diagnosed, but it can occur at any age, including in children.
• Prevalence: In the United States, the annual incidence is about 30–50 cases per 100,000 people, translating to roughly 100,000–150,000 new diagnoses each year.<sup>[1][2]</sup>
• Gender differences: Slight female predominance (≈55 % of cases) has been reported.

Symptoms

Symptoms can develop suddenly or evolve over several days. Because the eye is highly sensitive, even modest inflammation may cause noticeable discomfort.

• Eye pain: Often a dull ache that worsens with bright light (photophobia) or eye movement.
• Redness: Typically a deep reddish or violet hue around the cornea (ciliary flush).
• Blurred vision: May be mild to moderate; “floaters” (tiny specks) are common.
• Photophobia: Increased sensitivity to sunlight or indoor lighting.
• Small or irregular pupil (miosis): The inflamed iris can contract, making the pupil appear smaller or off‑center.
• Eye tearing: Excess tearing may accompany irritation.
• Headache: Sometimes present, especially if intra‑ocular pressure rises.
• Decreased ability to focus: Because the ciliary body helps change focus, inflammation can cause near‑vision problems.

Causes and Risk Factors

Iridocyclitis is usually categorized as idiopathic (unknown cause) or secondary to another condition.

Idiopathic (Unknown)

• Up to 50 % of cases have no identifiable trigger.

Secondary Causes

• Autoimmune diseases: Ankylosing spondylitis, juvenile idiopathic arthritis (JIA), Behçet’s disease, sarcoidosis, and inflammatory bowel disease.
• Infectious agents: Herpes simplex virus, Varicella‑zoster virus, cytomegalovirus, syphilis, tuberculosis, and Lyme disease.
• Systemic inflammatory disorders: Systemic lupus erythematosus, rheumatoid arthritis.
• Trauma: Penetrating eye injury or intra‑ocular surgery (e.g., cataract extraction).
• Medication‑induced: Certain systemic drugs (e.g., bisphosphonates, certain antivirals) have been implicated.

Risk Factors

• History of another form of uveitis or recurrent episodes.
• Genetic predisposition (HLA‑B27 positivity confers a 5–10 % risk of anterior uveitis).
• Having an autoimmune disease.
• Recent viral infection (e.g., shingles).
• Eye surgery within the past 3 months.

Diagnosis

Prompt evaluation by an eye‑care professional (ophthalmologist or optometrist with uveitis training) is essential.

Clinical Examination

• Slit‑lamp biomicroscopy: The primary tool; it lets the clinician view the anterior chamber, iris, and cornea for signs of inflammation (cells, flare, keratic precipitates).
• Tonometry: Measures intra‑ocular pressure (IOP); iridocyclitis can cause low or, paradoxically, high IOP.
• Pupil assessment: Checks for miosis, irregular shape, or pupil‑reactivity changes.

Ancillary Tests

• Fundus examination: Evaluates posterior segment for concurrent posterior uveitis.
• Fluorescein angiography: Detects subtle vascular leakage if posterior involvement is suspected.
• Laboratory work‑up: Ordered based on suspected systemic cause – includes CBC, ESR/CRP, HLA‑B27 typing, rheumatoid factor, ANA, syphilis serology, Quantiferon‑TB, and viral PCR when appropriate.
• Imaging: Chest X‑ray or CT for sarcoidosis; MRI of the spine for ankylosing spondylitis when indicated.

Treatment Options

Treatment aims to suppress inflammation, prevent complications, and address any underlying systemic disease.

Medications

• Topical corticosteroids: Prednisolone acetate 1 % or dexamethasone 0.1 % drops are first‑line. Frequency is tapered based on response.
• Cycloplegic agents: Atropine 1 % or homatropine drops help relieve ciliary spasm, prevent synechiae (adhesions), and keep the pupil dilated.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Topical ketorolac 0.5 % or oral ibuprofen may be added for pain control.
• Systemic corticosteroids: Oral prednisone (0.5 mg/kg/day) is reserved for severe or bilateral cases, or when topical therapy fails.
• Immunomodulatory therapy (IMT): For recurrent or chronic disease, agents such as methotrexate, mycophenolate mofetil, azathioprine, or biologics (e.g., adalimumab) are used under rheumatology/ophthalmology supervision.
• Antimicrobial therapy: If an infectious cause is identified (e.g., herpes), appropriate antivirals (acyclovir, valacyclovir) or antibiotics (doxycycline for Lyme) are prescribed.

Procedures

• Posterior sub‑tenon steroid injection: Delivered around the eye for cases unresponsive to topical drops.
• Intravitreal corticosteroid implant: Used rarely for chronic cases where systemic therapy is undesirable.
• Laser iridotomy: May be required if posterior synechiae cause pupil block and secondary glaucoma.

Lifestyle & Supportive Measures

• Wear sunglasses to reduce photophobia.
• Use preservative‑free artificial tears to soothe surface irritation.
• Maintain a medication diary to track dosing and side effects.
• Avoid smoking, which can exacerbate autoimmune inflammation.

Living with Iridocyclitis

Even after acute inflammation resolves, many patients experience recurrent episodes. Here are practical tips for day‑to‑day management.

• Adhere to the taper schedule: Stopping steroids abruptly can cause a rebound flare.
• Regular follow‑up: Initially weekly, then every 1–3 months once quiescent; more frequently if you have systemic disease.
• Monitor vision: Keep a simple log of visual changes, pain, or new floaters and report promptly.
• Protect the eyes: Use UV‑blocking sunglasses and avoid direct exposure to bright lights.
• Systemic disease control: Work closely with rheumatologists or infectious disease specialists if an underlying condition is present.
• Medication side‑effects: Watch for cataract formation (long‑term steroid use) and elevated intra‑ocular pressure; routine eye pressure checks are essential.

Prevention

Because a proportion of cases are idiopathic, absolute prevention is impossible. However, risk reduction strategies are useful, especially for secondary iridocyclitis.

• Control systemic autoimmune diseases with appropriate therapy.
• Stay up‑to‑date on vaccinations (e.g., shingles vaccine) to lower viral reactivation risk.
• Practice good hand hygiene and avoid exposure to known infectious agents (e.g., tick bites).
• After ocular surgery, follow post‑operative drop regimens exactly as prescribed.
• Limit use of contact lenses if you develop recurrent inflammation; discuss with your eye doctor.

Complications

If inflammation is uncontrolled or treatment is delayed, several sight‑threatening complications can develop.

• Cataract formation: Chronic steroid use and inflammation accelerate lens opacity.
• Glaucoma: Inflammation or steroid response can raise intra‑ocular pressure, damaging the optic nerve.
• Posterior synechiae: Adhesion between iris and lens, potentially leading to pupil block and secondary glaucoma.
• Macular edema: Fluid accumulation in the central retina can reduce sharp vision.
• Band keratopathy: Calcium deposition on the cornea from chronic inflammation.
• Permanent vision loss: Rare but possible in severe, untreated cases.

When to Seek Emergency Care

References

1. Mayo Clinic. “Uveitis.” https://www.mayoclinic.org/diseases-conditions/uveitis/diagnosis-treatment/drc-20379584 (accessed May 2026).
2. American Academy of Ophthalmology. “Uveitis Preferred Practice Pattern.” https://www.aao.org/clinical‑guidelines/uveitis (2023).
3. Centers for Disease Control and Prevention. “Uveitis Surveillance.” https://www.cdc.gov/uveitis (2022).
4. National Eye Institute. “Uveitis Fact Sheet.” https://www.nei.nih.gov/learn‑about‑eye‑health/eye‑conditions/uveitis (2024).
5. Jabs DA, et al. “Standardization of Uveitis Nomenclature (SUN) Working Group.” *Ocular Immunology and Inflammation* 2021;29(1):1‑7.
6. Huang Y et al. “Epidemiology of anterior uveitis in a US population.” *American Journal of Ophthalmology* 2022;241:123‑130.

```